In this study, a novel 8-DRG signature (MDC1, RPA3, MED17, DDB2, SFPQ, XRCC4, CYP19A1, and PARP3) was successfully identified to predict the survival of patients with BC in both the training and test cohorts. Here, XRCC4 is linked to breast cancer.